Hannah Clarke

Padcev and Keytruda improve survival and progression among patients with bladder cancer, but don’t adversely impact pain, functioning or quality of life.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.